Peptide Comparison
ChonlutenvsThymosin Alpha-1
Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
At a Glance
Quick
comparison
Dose Range
Chonluten
5–10 mg
Thymosin Alpha-1
1.6–3.2 mg
Frequency
Chonluten
Once daily
Thymosin Alpha-1
Twice weekly
Administration
Chonluten
Sublingual (enteric-coated capsules)
Thymosin Alpha-1
Subcutaneous injection
Cycle Length
Chonluten
12+ weeks
Thymosin Alpha-1
8-12 weeks
Onset Speed
Chonluten
Gradual (3-4 weeks)
Thymosin Alpha-1
Moderate (1-2 weeks)
Evidence Level
Chonluten
Limited human trials
Thymosin Alpha-1
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Respiratory Tissue Repair
Lung Inflammation Control
Age-Related Lung Protection
Immune Activation
Infection Fighting
Immune Balance
Technical Data
Compound
specifications
Chonluten
Molecular Formula
C11H17N3O8
Molecular Weight
319.27 g/mol
Half-Life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure
CAS Number
75007-24-8
Thymosin Alpha-1
Molecular Formula
C129H215N33O55
Molecular Weight
3108.32 g/mol
Half-Life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS Number
62304-98-7
Protocols
Dosing
tiers
Chonluten
Thymosin Alpha-1
Applications
Best
suited for
Chonluten
Respiratory health restoration in aging individuals with declining lung function
Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic bronchopulmonary conditions requiring tissue-level regenerative support
Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for lung tissue preservation in elderly populations
Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Alpha-1
Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.
Safety Profile
Side
effects
Chonluten
Common
- Injection site reaction
- Mild fatigue
- Transient respiratory changes
- Mild headache
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
Thymosin Alpha-1
Common
- Injection site reactions
- Mild fatigue
- Flu-like symptoms
Uncommon
- Mild fever
- Lymph node awareness
Serious
- Allergic reaction
Research Status
Safety
& evidence
Chonluten
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive pulmonary infections requiring immediate medical treatment
- xSevere immunosuppression without medical supervision — immunomodulatory effects may be unpredictable
Thymosin Alpha-1
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for other use
Safety Overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.
Contraindications
- xOrgan transplant recipients on immunosuppressants
- xActive autoimmune disease flares
- xKnown allergy to thymosin peptides
- xPregnancy or breastfeeding
- xChildren under 18 without medical supervision
Decision Guide
Which is
right for you?
Choose Chonluten if...
- Respiratory health restoration in aging individuals with declining lung function
- Chronic bronchopulmonary conditions requiring tissue-level regenerative support
- Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
- Geroprotective therapy for lung tissue preservation in elderly populations
Choose Thymosin Alpha-1 if...
- Immune system strengthening
- Chronic infection support
- Cancer adjunct therapy
- Healthy aging immune support